Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer. Guerin will help guide the company as its lead drug candidate, buntanetap, advances through late-stage trials targeting Alzheimer’s and Parkinson’s diseases.
Guerin previously served as CFO of Onconova Therapeutics, now Traws Pharma (NASDAQ: TRAW), where he oversaw multiple financings and a merger that formed the new entity. His earlier roles include senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand. Guerin said he is eager to support Annovis as it works to replicate buntanetap’s early success in registrational studies and deliver solutions for patients with Alzheimer’s and Parkinson’s disease.
The appointment comes at a critical time for Annovis, as buntanetap moves closer to potential regulatory approval. The company’s platform focuses on addressing neurodegeneration by targeting multiple pathways implicated in disease progression. Annovis is headquartered in Malvern, Pennsylvania, and is dedicated to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit the company’s website at www.annovisbio.com.
Guerin’s experience in corporate finance and mergers is expected to be instrumental as Annovis navigates the complexities of late-stage clinical development and potential commercialization. The company’s newsroom, available at https://ibn.fm/ANVS, provides the latest updates on ANVS.
This announcement underscores Annovis’s commitment to advancing its pipeline and preparing for the financial and operational demands of bringing a new therapy to market. The full press release is available at https://ibn.fm/AmfSU.
